Cardiovascular implications of HIV-induced dyslipidemia

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 384-389

  Giannarelli, Chiara ^a   Klein, Robert S ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Dyslipidemia; HIV

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ATAZANAVIR; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; EFAVIRENZ; EZETIMIBE; FENOFIBRIC ACID PLUS ROSUVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INTERLEUKIN 6; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEVIRAPINE; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIDOVUDINE;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY CALCIFICATION; DIET; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID STORAGE; LIVER DYSFUNCTION; MONOTHERAPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; VASCULAR DISEASE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DIET; DRUG SUBSTITUTION; DYSLIPIDEMIAS; EARLY DIAGNOSIS; EXERCISE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 82955212878     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.003     Document Type: Review

References (72)

1. Ford E.S., Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol 2007, 50:2128-2132.
2. Dube M.P., Lipshultz S.E., Fichtenbaum C.J., Greenberg R., Schecter A.D., Fisher S.D. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008, 118:e36-e40.
3. Giannarelli C., Zafar M.U., Badimon J.J. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?. Thromb Haemost 2010, 104:949-954.
4. Lupattelli G., Marchesi S., Roscini A.R., et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am J Cardiol 2002, 90:648-650.
5. Rodriguez C., Slevin M., Rodriguez-Calvo R., et al. Modulation of endothelium and endothelial progenitor cell function by low-density lipoproteins: implication for vascular repair, angiogenesis and vasculogenesis. Pathobiology 2009, 76:11-22.
6. Santos-Gallego C.G, Ibanez B., Badimon J.J. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol 2008, 76:443-452.
7. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
8. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
9. Mocroft A., Ledergerber B., Katlama C., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
10. Effros R.B., Fletcher C.V., Gebo K., et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008, 47:542-553.
11. Friis-Moller N., Sabin C.A., Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
12. Iloeje U.H., Yuan Y., L'Italien G., et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005, 6:37-44.
13. Kwong G.P., Ghani A.C., Rode R.A., et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006, 20:1941-1950.
14. Friis-Moller N., Reiss P., Sabin C.A., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
15. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.
16. Phillips A.N., Carr A., Neuhaus J., et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008, 13:177-187.
17. Kuller L.H., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
18. Triant V.A., Meigs J.B., Grinspoon S.K. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009, 51:268-273.
19. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
20. Temelkova-Kurktschiev T., Hanefeld M. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 2004, 112:75-79.
21. Mildvan D., Machado S.G., Wilets I., Grossberg S.E. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992, 339:453-456.
22. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., Feingold K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
23. Worm S.W., De Wit S., Weber R., et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009, 119:805-811.
24. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978-2982.
25. Stein J.H., Komarow L., Cotter B.R., et al. Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG study A5152s stein: lipoprotein changes on antiretroviral therapy. J Clin Lipidol 2008, 2:464-471.
26. Torriani F.J., Komarow L., Parker R.A., et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J Am Coll Cardiol 2008, 52:569-576.
27. Dube M.P., Gorski J.C., Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol 2008, 8:15-22.
28. Oliviero U., Bonadies G., Apuzzi V., et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2009, 204:586-589.
29. Kristoffersen U.S., Wiinberg N., Petersen C.L., et al. Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nucl Med Commun 2010, 31:874-880.
30. Teixeira H.N., Mesquita E.T., Ribeiro M.L., et al. Study of vascular reactivity in HIV patients whether or not receiving protease inhibitor. Arq Bras Cardiol 2009, 93:360-366. 367-73.
31. Hsue P.Y., Hunt P.W., Wu Y., et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009, 23:2021-2027.
32. Dube M.P., Shen C., Mather K.J., Waltz J., Greenwald M., Gupta S.K. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses 2010, 26:847-854.
33. Andrade A.C., Ladeia A.M., Netto E.M., et al. Cross-sectional study of endothelial function in HIV-infected patients in Brazil. AIDS Res Hum Retroviruses 2008, 24:27-33.
34. Dube M.P., Shen C., Greenwald M., Mather K.J. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008, 47:567-574.
35. Friis-Moller N., Worm S.W. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?. Clin Infect Dis 2007, 45:1082-1084.
36. Parra S., Coll B., Aragones G., et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010, 11:225-231.
37. Lorenz M.W., Stephan C., Harmjanz A., et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008, 196:720-726.
38. Grunfeld C., Delaney J.A., Wanke C., et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009, 23:1841-1849.
39. Hsue P.Y., Squires K., Bolger A.F., et al. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation 2008, 118:e41-e47.
40. Lebech A.M., Wiinberg N., Kristoffersen U.S., et al. Carotid intima-media thickness in HIV patients treated with antiretroviral therapy. Clin Physiol Funct Imaging 2007, 27:173-179.
41. Tincati C., Bellistri G.M., Casana M., et al. CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease. J Acquir Immune Defic Syndr 2009, 51:642-644.
42. Falcone E.L., Mangili A., Skinner S., Alam A., Polak J.F., Wanke C.A. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther 2011, 16:1-8.
43. Fitch K.V., Lo J., Abbara S., et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr 2010, 55:495-499.
44. Lo J., Abbara S., Shturman L., et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010, 24:243-253.
45. Martinez E. The NEFA study: results at three years. AIDS Rev 2007, 9:62.
46. Gatell J., Salmon-Ceron D., Lazzarin A., et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007, 44:1484-1492.
47. Moyle G.J., Sabin C.A., Cartledge J., et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043-2050.
48. Dube M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
49. Gerber J.G., Rosenkranz S.L., Fichtenbaum C.J., et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005, 39:307-312.
50. Aberg J.A, Zackin R.A., Brobst S.W., et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005, 21:757-767.
51. Calza L., Colangeli V., Manfredi R., et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005, 19:1103-1105.
52. Kiser J.J., Gerber J.G., Predhomme J.A., Wolfe P., Flynn D.M., Hoody D.W. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008, 47:570-578.
53. van der Lee M., Sankatsing R., Schippers E., et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007, 12:1127-1132.
54. Calza L., Manfredi R., Colangeli V., Pocaterra D., Pavoni M., Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008, 6:572-578.
55. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
56. Villines T.C., Stanek E.J., Devine P.J., et al. The ARBITER 6-HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010, 55:2721-2726.
57. Guyton J.R., Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 2007, 99:22C-31C.
58. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA 2000, 284:1263-1270.
59. Brinton E.A. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?. Curr Atheroscler Rep 2008, 10:25-32.
60. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
61. Oh J., Hegele R.A. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007, 7:787-796.
62. Enger C., Gately R., Ming E.E., Niemcryk S.J., Williams L., McAfee A.T. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010, 106:1594-1601.
63. McGoldrick C., Leen C.L. The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Med 2007, 8:325-334.
64. Jones P.H., Davidson M.H., Kashyap M.L. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2008.
65. Akdim F., Kastelein J.J., Gaudet D. The ENHANCE study and marketing ezetimibe. JAMA 2008, 299. author reply 2747-2748.
66. Coll B., Aragones G., Parra S., Alonso-Villaverde C., Masana L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006, 20:1675-1677.
67. Wohl D.A., Waters D., Simpson R.J., et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008, 47:1105-1108.
68. Berg-Wolf M.V., Klibanov O.M., Gaughan J.P., Tedaldi E.M. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS 2008.
69. Townsend M.L., Hollowell S.B., Bhalodia J., Wilson K.H., Kaye K.S., Johnson M.D. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS 2007, 18:851-855.
70. Pere D., Ignacio S.L., Ramon T., et al. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Open AIDS J 2008, 2:26-38.
71. Glass T.R., Ungsedhapand C., Wolbers M., et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006, 7:404-410.
72. Manfredi R., Calza L., Chiodo F. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration. J Biol Regul Homeost Agents 2006, 20:1-9.